Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cytokine gene polymorphisms and breast cancer susceptibility and prognosis*

Cytokine gene polymorphisms and breast cancer susceptibility and prognosis* Single nucleotide polymorphisms (SNPs) in the promoter regions of cytokine genes are associated with differential levels of cytokine expression. We hypothesized that these SNPs might influence breast tumour development and progression by affecting the efficiency of the antitumour immune response and/or pathways of angiogenesis. A total of 144 female breast cancer patients and 263 cancer‐free population controls were genotyped for the interleukin (IL)‐1β−511 (T/C), IL‐6 −174 (G/C), tumour necrosis factor (TNF)‐α−308 (A/G), IL‐10 −1082 (A/G), IL‐8 −251 (A/T) and vascular endothelial growth factor (VEGF) −1154 (A/G) SNPs, using amplification refractory mutation system polymerase chain reaction (ARMS‐PCR) and TaqMan® (Applied Biosystems, Foster City, CA, USA) 5′ nuclease assays for allelic discrimination. No significant associations were seen. Patient–control comparisons revealed a non‐significant trend for association between the TNF‐α−308 GG genotype and breast cancer compared to controls (79.7 vs. 68.2%, P = 0.03, Pc = 0.54). Stratification of the patient group according to the Nottingham Prognostic Index and individual prognostic factors revealed trends for association between IL‐6 −174 GC and IL‐8 −251 AA genotypes and markers of poor prognosis (P = 0.04, Pc = 0.72 and P = 0.02, Pc = 0.36, respectively). There were also trends for associations between VEGF −1154 AG and IL‐1β−511 TC genotypes and markers of good prognosis (P = 0.02, Pc = 0.36 and P = 0.05, Pc = 0.90, respectively). These results suggest that the role of cytokine promoter SNPs in both susceptibility to and prognosis in breast cancer requires further investigation in a larger study. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Immunogenetics Wiley

Cytokine gene polymorphisms and breast cancer susceptibility and prognosis*

Loading next page...
 
/lp/wiley/cytokine-gene-polymorphisms-and-breast-cancer-susceptibility-and-vDR54J0dOD

References (40)

Publisher
Wiley
Copyright
Copyright © 2004 Wiley Subscription Services, Inc., A Wiley Company
ISSN
1744-3121
eISSN
1744-313X
DOI
10.1111/j.1365-2370.2004.00462.x
Publisher site
See Article on Publisher Site

Abstract

Single nucleotide polymorphisms (SNPs) in the promoter regions of cytokine genes are associated with differential levels of cytokine expression. We hypothesized that these SNPs might influence breast tumour development and progression by affecting the efficiency of the antitumour immune response and/or pathways of angiogenesis. A total of 144 female breast cancer patients and 263 cancer‐free population controls were genotyped for the interleukin (IL)‐1β−511 (T/C), IL‐6 −174 (G/C), tumour necrosis factor (TNF)‐α−308 (A/G), IL‐10 −1082 (A/G), IL‐8 −251 (A/T) and vascular endothelial growth factor (VEGF) −1154 (A/G) SNPs, using amplification refractory mutation system polymerase chain reaction (ARMS‐PCR) and TaqMan® (Applied Biosystems, Foster City, CA, USA) 5′ nuclease assays for allelic discrimination. No significant associations were seen. Patient–control comparisons revealed a non‐significant trend for association between the TNF‐α−308 GG genotype and breast cancer compared to controls (79.7 vs. 68.2%, P = 0.03, Pc = 0.54). Stratification of the patient group according to the Nottingham Prognostic Index and individual prognostic factors revealed trends for association between IL‐6 −174 GC and IL‐8 −251 AA genotypes and markers of poor prognosis (P = 0.04, Pc = 0.72 and P = 0.02, Pc = 0.36, respectively). There were also trends for associations between VEGF −1154 AG and IL‐1β−511 TC genotypes and markers of good prognosis (P = 0.02, Pc = 0.36 and P = 0.05, Pc = 0.90, respectively). These results suggest that the role of cytokine promoter SNPs in both susceptibility to and prognosis in breast cancer requires further investigation in a larger study.

Journal

International Journal of ImmunogeneticsWiley

Published: Aug 1, 2004

There are no references for this article.